Loading
A phase 2 trial of Enzalutamide, Abiraterone acetate, Prednisone in prostate cancer, run by Astellas Pharma Global Development, Inc., active and no longer recruiting.
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study is a phase 2 interventional study registered as NCT02960022 by Astellas Pharma Global Development, Inc., with 900 participants planned, started 2016-12-22 and due to reach its primary completion in 2029-07-31. Interventions recorded: enzalutamide, abiraterone acetate, prednisone, Leuprolide acetate. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.
Shares Astellas, Abiraterone acetate, Prednisone, Prostate cancer.
Shares Astellas, Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prednisone, Prostate cancer.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Abiraterone acetate, Prednisone, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Prostate cancer.